BioSpace News Archive

The Texas Mesothelioma Victims Center says, “We are making instant access to the lawyers at the law firm of Karst von Oiste a top priority for a US Navy Veteran in Texas who has been diagnosed with this rare cancer, especially if the Veteran was exposed to asbestos while working on a ship as a machinist mate, boiler technician, electrician or mechanic.

Eon is excited to bring top minds together to answer the tough questions and discuss innovative healthcare solutions and the patient impact they could have.

The Society of Plastic Surgical Skin Care Specialists (SPSSCS) announced Susan Eldridge, Aesthetician of Portland, OR as its new President today at the 25th Anniversary Meeting of the Society

When executives at Chinese pharmaceuticals firm Innovent were looking for a base, the eastern city of Suzhou seemed like a natural fit.

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will be presenting at the following events taking place in May and June.

GateHouse Treatment and GH Recovery Solutions, New England’s premier providers of drug and alcohol treatment programs, today announced that Samuel MacMaster, Ph.D. has joined the organization as Chief Science Officer.

The Epilepsy Foundation is hosting its 13th Annual Care & Cure Benefit on May 30, 2019, at 6 p.m. at the Beverly Wilshire Hotel in Beverly Hills.

Rebiotix Inc, a Ferring company, will present data highlighting clinical trials of RBX2660 and RBX7455, two formulations of investigational microbiome restoration therapeutics being studied for the prevention of recurrent Clostridioides (Clostridium) difficile (C. diff) infection, at the 2019 Digestive Disease Week© (DDW) meeting, taking place May 18-21 in San Diego, California.

Cross Country Healthcare, a national leader in providing innovative healthcare workforce solutions and staffing services, announced that it has placed one of its travel nurses on her 100th assignment with the company.

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies that unlock the full potential of proven medicines for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced a poster presentation at the upcoming American Psychiatric Association (APA) Annual Meeting,